BridgeBio secures $200M from VCs for oncology spinout’s KRAS breakthrough
TLDR: BridgeBio Pharma has secured $200 million in venture capital to fund its cancer-focused spinout, BridgeBio Oncology Therapeutics (BBOT). BBOT is focused on developing a pipeline of KRAS inhibitors with the goal